Abstract #989981: Three Cases of Hypoparathyroidism Treated Successfully with Daily Recombinant Human Parathyroid Hormone rhPTH (1-84; Natpara) Subcutaneous Injections, with Improvement in the Quality of Life and Reduction in Daily Calcium and Vitamin D Requirements

Hypoparathyroidism is a rare endocrine disorder which leads to hypocalcemia, hypercalciuria, and hyperphosphatemia. Complications include nephrocalcinosis with renal dysfunction, reduced quality of life, and abnormal skeletal properties. Conventional therapy with calcium and vitamin D analogs addresses hypocalcemia but has important limitations. Parathyroid hormone (PTH) therapy is a fundamental advance, although the effects of PTH on long-term complications require additional testing. Continuous PTH therapy is likely to be particularly advantageous for addressing renal, quality of life, and skeletal complications. Overall, much progress has been made, yet more information is needed to improve our understanding and management of hypoparathyroidism.

Download Full-text

Teriparatide Administration By The Omnipod Pump: A Self-Managed Therapeutic Option for Refractory Hypoparathyroidism

10.21203/rs.3.rs-1002651/v1 ◽

2021 ◽

Author(s):

Karine Aouchiche ◽

Rachel Reynaud ◽

Vincent Amodru ◽

Thierry Brue ◽

Thomas Cuny

Keyword(s):

Quality Of Life ◽

Vitamin D ◽

Total Thyroidectomy ◽

Therapeutic Option ◽

Review Of Literature ◽

Active Vitamin ◽

Continuous Administration ◽

Subcutaneous Injections ◽

Subcutaneous Infusion

Abstract Context : Hypoparathyroidism (hypoPTH) in adults is mainly due to total thyroidectomy. Conventional therapies (calcium, active vitamin D) can fail to normalize calcemia, expose the patient to hypercalciuria and impact quality-of-life. Human parathormone (hPTH) replacement therapy is a suitable option in these cases, although few clinical reports have been published so far. Methods we describe two cases of refractory postsurgical hypoPTH for which subcutaneous infusion of recombinant parathormone (teriparatide) through the Omnipod® pump was started after failure of all other therapeutic options. Besides, we performed a review of literature of hypoPTH cases treated by continuous infusion of teriparatide. Results two women aged 46 and 61yo failed to normalize calcemia either with conventional treatments (calcium 8g/d + calcitriol 9µg/d and calcium 5g/d + calcitriol 12µg/d) or with thrice-daily subcutaneous injections of teriparatide. As a last resort, teriparatide infusion via Omnipod® device normalized their calcemia and allowed calcium/vitamin D withdrawal, with average teriparatide dose of 23 and 32 µg/day, respectively. Notably, a dedicated protocol currently allow each patient to be autonomous with its pump without adverse dyscalcemia until now. In the literature, 15 adult cases (13 women, mean age 44.5 ± 5.2 yo) are reported. HypoPTH was consecutive to surgery in all of them. Mean dose of teriparatide administered was 25 ± 6 µg/d with improvement of calcemia level and quality-of-life in all patients. Conclusion Continuous administration of teriparatide through Omnipod® is a safe and efficient therapeutic option in refractory hypoPTH, which can, furthermore, be safely self-managed by the patient.

Download Full-text

Faculty Opinions recommendation of Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732070903.793576363 ◽

2020 ◽

Author(s):

Mishaela Rubin

Keyword(s):

Quality Of Life ◽

Parathyroid Hormone ◽

Health Related Quality ◽

Human Parathyroid Hormone ◽

Hormone Effect ◽

Related Quality ◽

Health Related ◽

Chronic Hypoparathyroidism

Download Full-text

Vitamin D deficiency and depression among women from an urban community in a tropical country

Public Health Nutrition ◽

10.1017/s1368980016000811 ◽

2016 ◽

Vol 20 (10) ◽

pp. 1844-1850 ◽

Cited By ~ 7

Author(s):

Foong Ming Moy ◽

Victor CW Hoe ◽

Noran Naqiah Hairi ◽

Shireene Ratna Vethakkan ◽

Awang Bulgiba

Keyword(s):

Quality Of Life ◽

Mental Health ◽

Vitamin D ◽

Parathyroid Hormone ◽

Vitamin D Deficiency ◽

Health Related Quality ◽

Kuala Lumpur ◽

Related Quality ◽

Health Related

AbstractObjectiveTo determine the association of vitamin D status with depression and health-related quality of life among women.DesignThis was a cross-sectional study conducted among women in Kuala Lumpur, Malaysia. Sociodemographic characteristics, physical activity status, perceived depression and health-related quality of life were assessed via a self-administered questionnaire. Fasting blood samples were taken for the analysis of 25-hydroxyvitamin D, parathyroid hormone, fasting blood glucose and full lipid profile. Complex samples multiple logistic regression analysis was performed.SettingPublic secondary schools in Kuala Lumpur, Malaysia.SubjectsSeven hundred and seventy female teachers were included.ResultsThe mean age of participants was 41·15 (95 % CI 40·51, 41·78) years and the majority were ethnic Malays. Over 70 % of them had vitamin D deficiency (<20 ng/ml or <50 nmol/l) and two-thirds were at risk for depression. In the multivariate analysis, ethnic Malays (adjusted OR (aOR)=14·72; 95 % CI 2·12, 102·21) and Indians (aOR=14·02; 95 % CI 2·27, 86·59), those at risk for depression (aOR=1·88, 95 % CI 1·27, 2·79) and those with higher parathyroid hormone level (aOR=1·13; 95 % CI 1·01, 1·26) were associated with vitamin D deficiency, while vitamin D deficiency was negatively associated with mental health-related quality of life (Mental Component Summary) scores (aOR=0·98; 95 % CI 0·97, 0·99).ConclusionsVitamin D deficiency is significantly associated with depression and mental health-related quality of life among women in Kuala Lumpur, Malaysia.

Download Full-text